

WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma

Authors

Rosa A. van Amerongen, Renate S. Hagedoorn, Dennis F.G. Remst, Danique C. Assendelft, Dirk M. van der Steen, Anne K. Wouters, Marian van de Meent, Michel G.D. Kester, Arnoud H. de Ru, Marieke Griffioen, Peter A. van Veelen, J.H. Frederik Falkenburg and Mirjam H.M. Heemskerk.

Correspondence

m.h.m.heemskerk@lumc.nl

In brief

With newly identified Wilms' tumor gene 1 (WT1) peptides, derived from the HLA class I associated ligandome of primary acute myeloid leukemia (AML) and ovarian carcinoma (OVCA) samples, high-avidity WT1-specific T-cell clones were identified in the allogeneic-HLA T-cell repertoire of healthy donors. Using broad panels of malignant cells and healthy cell subsets, four WT1-specific TCRs were selected as promising candidates for TCR gene transfer strategies in AML and OVCA patients.

